Online Program

327030
Substance Use and HIV Prevention Efforts in a 50+ African American Population


Tuesday, November 3, 2015 : 11:30 a.m. - 11:50 a.m.

Carlton Williams, D. Min., Substance Abuse Resources and Disability Issues (SARDI), Boonshoft School of Medicine, Wright State University, Kettering, OH
Kevin Kissell, B.S., Substance Abuse Resources and Disability Issues (SARDI), Boonshoft School of Medicine, Wright State University, Kettering, OH
Nicole Kinzeler, Ph.D, Substance Abuse Resources and Disability Issues (SARDI), Boonshoft School of Medicine, Wright State University, Kettering, OH
Leon Hardin, MBA, Substance Abuse Resources and Disability Issues (SARDI), Boonshoft School of Medicine, Wright State University, Kettering, OH
Karen Brown, Substance Abuse Resources and Disability Issues (SARDI), Boonshoft School of Medicine, Wright State University, Kettering, OH
Josephine Wilson, DDS, PhD, Substance Abuse Resources and Disability Issues (SARDI), Boonshoft School of Medicine, Wright State University, Kettering, OH
Background: African-Americans, 50 and older, are an emerging group with increased risk for substance abuse and HIV infection. The Fifty Plus Prevention Program (F3P) was designed to address the lack of prevention efforts targeting this unique and under-represented population. Utilizing an evidence-based intervention (SHIELD), HIV testing, and peer advocates, the program sought to reduce substance use, increase HIV knowledge, and change attitudes toward perceived risk associated with HIV and substance use. Methods: Participants were recruited from local urban housing complexes that were predominantly occupied by the target population. They attended SHIELD, a six-session intervention, specifically adapted to be age appropriate and culturally significant. Participants were also encouraged to be tested for HIV and train as peer advocates. Outcome measures, including substance use,  HIV knowledge and perceived risk scores, were obtained from self-reported data at baseline and six-month follow-up (n=261). Results: Nearly 75% of participants attended  five or more sessions of SHIELD, 80% were tested for HIV, and fifteen peer advocates educated nearly 1200 members of the community. Of those enrolled, paired samples t-tests showed significant reductions in marijuana and illegal drug use from baseline to follow-up. Additionally, participants demonstrated a statistically significant increase in both HIV knowledge and perceived risk associated with substance use and sexual behavior. Conclusions: The F3P program had a positive impact on its participants.  In particular, participants demonstrated significant changes in their substance use, HIV knowledge, and risk perception attitudes. These changes accentuate the need for further prevention efforts targeting the unique risk factors associated with an older population.

Learning Areas:

Conduct evaluation related to programs, research, and other areas of practice
Implementation of health education strategies, interventions and programs
Protection of the public in relation to communicable diseases including prevention or control
Public health or related research

Learning Objectives:
Describe the strategies and outcomes of the Substance Abuse Resources & Disability Issues (SARDI) program to reduce substance use and increase HIV knowledge in an older African American population in urban Dayton, Ohio.

Keyword(s): African American, HIV/AIDS

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: Dr. Carlton Williams has been Assistant Research Professor in the Department of Community Health in the Boonshoft School of Medicine since 2009. He is regarded as a national authority on HIV prevention for African Americans and has conducted research in this area for over a decade. Dr. Williams is currently PI on two five-year, multi-million-dollar SAMHSA-funded HIV prevention projects targeting African Americans.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

Back to: 4136.0: HIV and Substance Use II